3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
14
Nivolumab
13
Sunitinib
12
Axitinib
9
cabozantinib
8
belzutifan
8
Ipilimumab
7
Everolimus
5
atezolizumab
4
Sorafenib
4
temsirolimus
3
perifosine
3
motexafin gadolinium
3
Drug Therapy
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
lenvatinib
2
entinostat
2
ciforadenant
2
belinostat
2
avelumab
2
Paclitaxel
2
Immunotherapy
2
G250 monoclonal antibody
2
Fluorouracil
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Kidney Neoplasms
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled